The European Medicines Agency (EMA) has approved the use of the Moderna vaccine among youths between the ages of 12 and 17. This means Malta can now start using the jab on this age group, with the second injection given four weeks after the first.
Before this new approval, the Pfizer BioNTech vaccine was the only one being used on this same age group. In an ongoing study that was carried out in accordance with Moderna’s paediatric investigation plan, the effects of this jab were researched in a study involving 3,732 children aged 12 to 17.
The study confirmed Moderna producing a comparable antibody response in this age group as it did in the 18 to 25 group. The EMA concluded that the efficacy of the vaccine in this age group was comparable to that in adults, ruling that the safety and efficacy of the jab far outweighed the risks posed by the virus.
Photo Source: Open Access Government